TY - JOUR
KW - Cprd
KW - Immune checkpoint inhibitors
KW - Lung cancer
KW - Study eligibility
KW - Tyrosine kinase inhibitors
AU - A. van Veelen
AU - S. Abtahi
AU - P. Souverein
AU - J. Driessen
AU - O. Klungel
AU - A. Dingemans
AU - R. van Geel
AU - F. de Vries
AU - S. Croes
AD - Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands; CARIM School of Cardiovascular Disease, Maastricht University Medical Centre+, Maastricht, The Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands; CARIM School of Cardiovascular Disease, Maastricht University Medical Centre+, Maastricht, The Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; NUTRIM, Maastricht University Medical Centre+, Maastricht, The Netherlands.
Department of Pulmonology, Erasmus MC, Rotterdam, The Netherlands.
Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands; CARIM School of Cardiovascular Disease, Maastricht University Medical Centre+, Maastricht, The Netherlands.
Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands; CARIM School of Cardiovascular Disease, Maastricht University Medical Centre+, Maastricht, The Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; MRC Lifecourse Epidemiology Unit, Southampton General Hospital, University of Southampton, SO16 6YD, UK.
Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands; CARIM School of Cardiovascular Disease, Maastricht University Medical Centre+, Maastricht, The Netherlands. Electronic address: s.croes@mumc.nl.
AN - 35429893
BT - Cancer Epidemiol
DO - 10.1016/j.canep.2022.102149
DP - NLM
ET - 2022/04/17
LA - eng
N1 - 1877-783x
van Veelen, Ard
Abtahi, Shahab
Souverein, Patrick
Driessen, Johanna H M
Klungel, Olaf H
Dingemans, Anne-Marie C
van Geel, Robin
de Vries, Frank
Croes, Sander
Journal Article
Netherlands
Cancer Epidemiol. 2022 Apr 13;78:102149. doi: 10.1016/j.canep.2022.102149.
PY - 2022
SN - 1877-7821
EP - 102149
T2 - Cancer Epidemiol
TI - Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors
VL - 78
ER -